BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37184988)

  • 1. Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study.
    Bankar A; Chan WC; Liu N; Cheung M; Alibhai S; Gupta V
    Blood Adv; 2023 Sep; 7(17):5014-5026. PubMed ID: 37184988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
    Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
    Price GL; Davis KL; Karve S; Pohl G; Walgren RA
    PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y; Lee JO; Bang SM
    J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA; Smith-Gagen JA
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.
    Larsen MK; Skov V; Kjær L; Eickhardt-Dalbøge CS; Knudsen TA; Kristiansen MH; Sørensen AL; Wienecke T; Andersen M; Ottesen JT; Gudmand-Høyer J; Snyder JA; Andersen MP; Torp-Pedersen C; Poulsen HE; Stiehl T; Hasselbalch HC; Ellervik C
    Blood Cancer J; 2024 Feb; 14(1):28. PubMed ID: 38331919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
    Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
    Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
    Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
    Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada.
    Bankar A; Zhao H; Iqbal J; Coxford R; Cheung MC; Mozessohn L; Earle CC; Gupta V
    Leuk Lymphoma; 2020 Aug; 61(8):1908-1919. PubMed ID: 32323602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
    Roaldsnes C; Holst R; Frederiksen H; Ghanima W
    Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
    Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
    Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
    Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
    Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing Frailty In Myeloproliferative Neoplasms: results from the ORCHID study.
    Chornenki NLJ; Siegal DM; Qamar K; Woolgar S; Rangarajan S; Karampatos S; Leong DP; Hillis CM
    Leuk Res; 2022 Feb; 113():106788. PubMed ID: 35042128
    [No Abstract]   [Full Text] [Related]  

  • 18. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
    Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
    Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Shallis RM; Zeidan AM; Wang R; Podoltsev NA
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-Specific Derangement of Circulating Endocannabinoids and
    Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.